Dr. Dimitry Ofengeim is head of the precision neurology and neuroinflammation cluster at Sanofi. He completed his PhD at the Albert Einstein College of Medicine and his postdoctoral training at Harvard Medical School. Prior to his current role, Dr. Ofengeim was the lab head for neuroimmunology research at Sanofi and a scientist at Biogen.
Associated Grants
-
Evaluation of the Inflammation-blocking Drug Tolebrutinib as a Novel Disease-modifying Therapeutic for Parkinson's Disease
2023